



IFW
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Daniel Achard, et al

Examiner: To Be Assigned

Application No.: **10/771,764**

Art Unit: **1624**

Filed: **February 4, 2004**

Title: **Pharmaceutical Compositions Containing 3-Aminoazetidine Derivatives, Novel Derivatives and Their Preparation**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 26, 2004

Date of Deposit

Bonnie Stein
Signature

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner of Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:


Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits,

whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

- (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.


Respectfully submitted,



Irving Newman, Reg. No. 22,638
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-**2785**
Telefax (908) 231-2626
Aventis Docket No. USST00008US CNT1

Please type a plus sign (+) inside this box →



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/771,764
Filing Date	02-04-2004
First Named Inventor	ACHARD
Group Art Unit	1624
Examiner Name	Not Yet Assigned
Attorney Docket Number	USST00008 - US - CNT - 1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CONSROE et al, Potential Role of Cannabinoids for Therapy of Neurological Disorders, Marijuana / Cannabinoids Neurobiology and Neurophysiology, Murphy L. and Barthe A. Eds., CRC Press, Vol. 459, 1992, pp 459-524	
		DAVE, Acylative Dealkylation of N-tert-Butyl-3-substituted Azetidines: Facil Access to [1.1.0]Azabicyclobutane, 3-Hydroxyazetidinium Hydrochloride, and 3-Azetidinones, J. Org. Chem., Vol. 61, 1996, pp 5454-5455	
		HOLLISTER, Health Aspects of Cannabis, Pharm. Rev., Vol. 38, No. 1, 1986, pp 1-20	
		KATRITZKY et al, Novel Syntheses of 1,3,3-Trinitroazetidine , J. Heterocycl. Chem. Vol. 271, 31, 1994, pp 271-275	
		KUSTER et al, Aminoalkylindole Binding in Rat Cerebellum: Selective Displacement by Natural and Synthetic Cannabinoids, J. Pharmacol. Exp. Ther., Vol. 264, No. 3, 1993, pp 1352-1363	
		PERTWEE, Effects of cannabinoids on thermoregulation: a brief review, Marijuana '84 Proceedings of the Oxford Symposium on Cannabis, Harvey d. J. Eds, 1985, pp 263-277	
		SETH et al , Chemistry and Pharmacology of Cannabis, Progress in Drug Research, 1991, pp 71-114	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.